These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8430455)

  • 1. Complement activation in stored platelet concentrates.
    Miletic VD; Popovic O
    Transfusion; 1993 Feb; 33(2):150-4. PubMed ID: 8430455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitivity and specificity of plasma and urine complement split products as indicators of lupus disease activity.
    Manzi S; Rairie JE; Carpenter AB; Kelly RH; Jagarlapudi SP; Sereika SM; Medsger TA; Ramsey-Goldman R
    Arthritis Rheum; 1996 Jul; 39(7):1178-88. PubMed ID: 8670328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiologic inactivation of fluid phase C3b: isolation and structural analysis of C3c, C3d,g (alpha 2D), and C3g.
    Davis AE; Harrison RA; Lachmann PJ
    J Immunol; 1984 Apr; 132(4):1960-6. PubMed ID: 6607952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation and fragmentation of the third (C3) and the fourth (C4) components of complement: generation and isolation of physiologically relevant fragments C3c and C4c.
    Janatova J; Gobel RJ
    J Immunol Methods; 1985 Dec; 85(1):17-26. PubMed ID: 4078308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reflection of disease activity in rheumatoid arthritis by indices of activation of the classical complement pathway.
    Makinde VA; Senaldi G; Jawad AS; Berry H; Vergani D
    Ann Rheum Dis; 1989 Apr; 48(4):302-6. PubMed ID: 2785367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation by cellulosic dialysis membranes.
    Innes A; Farrell AM; Burden RP; Morgan AG; Powell RJ
    J Clin Pathol; 1994 Feb; 47(2):155-8. PubMed ID: 8132830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of a novel low affinity complement C3dg-binding protein of human platelets.
    Chen H; Marjan J; Cox AD; Devine DV
    J Immunol; 1994 Feb; 152(3):1332-8. PubMed ID: 8301135
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus--a possible link to venous thrombosis?
    Lood C; Eriksson S; Gullstrand B; Jönsen A; Sturfelt G; Truedsson L; Bengtsson AA
    Lupus; 2012 Nov; 21(13):1423-32. PubMed ID: 22878256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin activity and complement activation during storage of citrated platelet concentrates.
    Bode AP; Miller DT; Newman SL; Castellani WJ; Norris HT
    J Lab Clin Med; 1989 Jan; 113(1):94-102. PubMed ID: 2521240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b.
    Aguado MT; Lambris JD; Tsokos GC; Burger R; Bitter-Suermann D; Tamerius JD; Dixon FJ; Theofilopoulos AN
    J Clin Invest; 1985 Oct; 76(4):1418-26. PubMed ID: 2932466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the activation of the fourth component of complement (C4) with disease activity in systemic lupus erythematosus.
    Senaldi G; Makinde VA; Vergani D; Isenberg DA
    Ann Rheum Dis; 1988 Nov; 47(11):913-7. PubMed ID: 3264693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose intravenous immunoglobulin treatment activates complement in vivo.
    Mollnes TE; Høgåsen K; De Carolis C; Vaquero E; Nielsen EW; Fontana L; Perricone R
    Scand J Immunol; 1998 Sep; 48(3):312-7. PubMed ID: 9743219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preferential activation of the alternative pathway of complement in psoriatic lesional skin.
    Takematsu H; Tagami H
    Dermatology; 1992; 184(2):159-60. PubMed ID: 1498383
    [No Abstract]   [Full Text] [Related]  

  • 15. A flow cytometric assay for measuring complement receptor 1 (CR1) and the complement fragments C3d and C4d on erythrocytes.
    Freysdottir J; Sigfusson A
    J Immunol Methods; 1991 Aug; 142(1):45-52. PubMed ID: 1833467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of the alternative pathway of complement in psoriatic lesional skin.
    Takematsu H; Tagami H
    Dermatologica; 1990; 181(4):289-92. PubMed ID: 2073958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes.
    Medof ME; Iida K; Mold C; Nussenzweig V
    J Exp Med; 1982 Dec; 156(6):1739-54. PubMed ID: 7175439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation in patients with rheumatoid arthritis mediated in part by C-reactive protein.
    Molenaar ET; Voskuyl AE; Familian A; van Mierlo GJ; Dijkmans BA; Hack CE
    Arthritis Rheum; 2001 May; 44(5):997-1002. PubMed ID: 11352263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bovine conglutinin binds to an oligosaccharide determinant presented by iC3b, but not by C3, C3b or C3c.
    Laursen SB; Thiel S; Teisner B; Holmskov U; Wang Y; Sim RB; Jensenius JC
    Immunology; 1994 Apr; 81(4):648-54. PubMed ID: 7518801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of immune precipitation by complement.
    Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
    J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.